Yole Développement Announces Foundation of BLUMORPHO
News Feb 17, 2015
Yole Développement (Yole) announces the founding of daughter company, BLUMORPHO SAS. BLUMORPHO’s mission is to create value from all forms of innovation.
BLUMORPHO is developing businesses for its customers by building a dynamic marketplace and is active all along the innovation chain, from research to market.
The spin-off will undertake Yole Finance Innovation activities dedicated to supporting technology exploitation, young companies’ maturation and intellectual property portfolio optimization.
“BLUMORPHO is operating an innovative business model in marketing a portfolio of attractive technologies to serve industrial needs and demand”, explains Géraldine Andrieux Gustin, CEO & Co-founder of BLUMORPHO. “We facilitate access to technologies and innovations with added value for industrial companies. Based on Yole’s expertise, and our hands-on experience, we identify bankable challenges in different industries and we match them with relevant solutions and technologies to address those needs. As a trusted third party active throughout the ecosystem, BLUMORPHO supports successful innovation processes”, she adds.
The concept of this new business model has been tested and validated in the course of COWIN, which was initiated and led by Géraldine as Yole Finance’s Senior Partner. Sponsored by the European Commission, COWIN was dedicated to facilitating the commercial exploitation of results from European research projects on smart systems. From 2010 to 2014, COWIN generated about 25 million Euros’ worth of investment opportunities in technology exploitation.
“The launch of BLUMORPHO is a natural continuation of COWIN. BLUMORPHO will contribute to maintaining COWIN’s momentum by working in close collaboration with European technology owners engaged in driving their innovations to market,” highlighted BLUMORPHO’s CEO & Co-founder.
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Rapid Test Helps with Administering the "Correct" DrugNews
In just three hours, a new rapid test will give information on which available antibiotic is still effective in a concrete case.READ MORE
Comments | 0 ADD COMMENT
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018
The Journey from Genes to Disease - a symposium for postdocs by postdocs.
Apr 20 - Apr 20, 2018